Search results
Results from the WOW.Com Content Network
The Ernst Ludwig Ehrlich Scholarship Fund (German: Ernst Ludwig Ehrlich Studienwerk or ELES for short) is one of thirteen Federally-funded Scholarship Foundations in the Federal Republic of Germany. It is located in Berlin. The Scholarship Fund was named after religious scholar and historian Ernst Ludwig Ehrlich (1921-2007).
The DAAD itself does not offer programs of study or courses, but awards competitive, merit-based grants for use toward study and/or research in Germany at any of the accredited German institutions of higher education. It also awards grants to German students, doctoral students, and scholars for studies and research abroad.
Alternatives to BAföG include the Bildungskredit ("study loan") from KfW, Bildungsfonds, and scholarships. However, in most cases to qualify for a private loan, one must have German citizenship, have EU citizenship and have resided in Germany for three consecutive years, or have graduated from a German secondary school.
A study published in April 2021 by researchers from the COVID-19 Genomics United Kingdom Consortium, the AMPHEUS Project, and the Oxford COVID-19 Vaccine Trial Group indicated the Oxford–AstraZeneca vaccine showed somewhat reduced efficacy against infection with the Alpha variant (lineage B.1.1.7), with 70.4% efficacy in absolute terms ...
The DRKS is an open access, free of charge online register for clinical trials and is available both in English and German. DRKS is part of the WHO's ICTRP. The DRKS works with two partner registries in Germany, DeReG (German Registry for Somatic Gene-Transfer Trials) and Clinical Trial Registry of the University Medical Center Freiburg. [4]
BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership ...
Single center, sequential dose-escalation, open labelled trial. Aug–Dec 2021, Germany: Phase I (42) [159] Single center, sequential dose-escalation, open labelled trial. Mar–Dec 2021, Netherlands: SCB-2020S Clover Biopharmaceuticals [160] China Subunit: Phase I–II (150) [161] Randomized, controlled, observer-blind. Aug 2021 – Apr 2022 ...
The trial, known as ADJUVANT BR.31 Phase III, sought to evaluate Imfinzi in the adjuvant treatment of 1,415 patients with an early stage of non-small-cell lung cancer following complete tumour ...